273 related articles for article (PubMed ID: 20416859)
1. [Lipid profile and cardiovascular risk in patients with rheumatoid arthritis: Effect of the disease and of drug therapy].
Hansel B; Bruckert E
Ann Endocrinol (Paris); 2010 Sep; 71(4):257-63. PubMed ID: 20416859
[TBL] [Abstract][Full Text] [Related]
2. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
[TBL] [Abstract][Full Text] [Related]
3. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
Naerr GW; Rein P; Saely CH; Drexel H
Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
[TBL] [Abstract][Full Text] [Related]
4. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.
Steiner G; Urowitz MB
Semin Arthritis Rheum; 2009 Apr; 38(5):372-81. PubMed ID: 18395771
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
6. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
[TBL] [Abstract][Full Text] [Related]
7. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis.
Seriolo B; Paolino S; Sulli A; Fasciolo D; Cutolo M
Ann N Y Acad Sci; 2006 Jun; 1069():414-9. PubMed ID: 16855168
[TBL] [Abstract][Full Text] [Related]
8. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.
Popa C; Netea MG; Radstake T; Van der Meer JW; Stalenhoef AF; van Riel PL; Barerra P
Ann Rheum Dis; 2005 Feb; 64(2):303-5. PubMed ID: 15231512
[TBL] [Abstract][Full Text] [Related]
9. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.
Amezaga Urruela M; Suarez-Almazor ME
Curr Rheumatol Rep; 2012 Oct; 14(5):428-37. PubMed ID: 22802154
[TBL] [Abstract][Full Text] [Related]
10. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis.
Popa C; van den Hoogen FH; Radstake TR; Netea MG; Eijsbouts AE; den Heijer M; van der Meer JW; van Riel PL; Stalenhoef AF; Barrera P
Ann Rheum Dis; 2007 Nov; 66(11):1503-7. PubMed ID: 17472994
[TBL] [Abstract][Full Text] [Related]
11. A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy.
Aguiar C; Alegria E; Bonadonna RC; Catapano AL; Cosentino F; Elisaf M; Farnier M; Ferrières J; Filardi PP; Hancu N; Kayikcioglu M; Mello E Silva A; Millan J; Reiner Ž; Tokgozoglu L; Valensi P; Viigimaa M; Vrablik M; Zambon A; Zamorano JL; Ferrari R
Atheroscler Suppl; 2015 Sep; 19():1-12. PubMed ID: 26315511
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk in patients with rheumatoid arthritis.
Lauper K; Gabay C
Semin Immunopathol; 2017 Jun; 39(4):447-459. PubMed ID: 28455580
[TBL] [Abstract][Full Text] [Related]
13. No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008.
Kerola AM; Nieminen TV; Virta LJ; Kautiainen H; Kerola T; Pohjolainen T; Kauppi MJ; Puolakka K
Clin Exp Rheumatol; 2015; 33(3):391-8. PubMed ID: 25936374
[TBL] [Abstract][Full Text] [Related]
14. Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis.
Toussirot É
Expert Opin Drug Saf; 2015 Apr; 14(4):525-32. PubMed ID: 25599626
[TBL] [Abstract][Full Text] [Related]
15. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis.
Liao KP; Playford MP; Frits M; Coblyn JS; Iannaccone C; Weinblatt ME; Shadick NS; Mehta NN
J Am Heart Assoc; 2015 Jan; 4(2):. PubMed ID: 25637346
[TBL] [Abstract][Full Text] [Related]
16. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study.
Coimbra S; Oliveira H; Reis F; Belo L; Rocha S; Quintanilha A; Figueiredo A; Teixeira F; Castro E; Rocha-Pereira P; Santos-Silva A
Am J Clin Dermatol; 2010 Dec; 11(6):423-32. PubMed ID: 20429617
[TBL] [Abstract][Full Text] [Related]
17. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
Danninger K; Hoppe UC; Pieringer H
Int J Rheum Dis; 2014 Jul; 17(6):606-11. PubMed ID: 24931356
[TBL] [Abstract][Full Text] [Related]
18. HDL-C: role as a risk modifier.
Barter P
Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
Rollefstad S; Ikdahl E; Hisdal J; Kvien TK; Pedersen TR; Holme I; Semb AG
Ann Rheum Dis; 2015 Aug; 74(8):1544-50. PubMed ID: 24699940
[TBL] [Abstract][Full Text] [Related]
20. Lipid profile and risks of cardiovascular diseases in conditions of rheumatoid arthritis.
Pašková U
Ceska Slov Farm; 2019; 68(6):219-228. PubMed ID: 31906689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
